Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Asian Pac J Cancer Prev. 2020 Sep 1;21(9):2561-2567. doi: 10.31557/APJCP.2020.21.9.2561.
Breast Cancer (BC), is one of the most common malignancies around the world. CD44 expression correlates with cell proliferation, infiltration, angiogenesis, metastasis and prognosis in breast cancer but the exact mechanism of CD44 function is still not clear. The present study evaluates the expression of CD44 in primary HER2-positive breast cancer. The results can be used to determine the disease-free and overall survival of patients with breast cancer.
We studied specimens from 100 patients with HER2-positive invasive breast cancer between March 2011 and June 2019. Immunohistochemical staining for CD44 was performed in all the specimens. Their CD44 association with clinicopathologic parameters and prognosis was evaluated.
The high CD44 was expression in 68(68%) of the patients and Low expression in 32(32%). CD44 expression was significantly associated with stage (p=0.007). There were no significant associations between the DFS, OS and other clinicopathologic parameters except for the stage, respectively (HR= 3.67, 95% CI =1.16-11.56, P = 0.03) (HR= 0.8.56, 95% CI =2.22-32.90, P = 0.002).20% of patients had died by the end of the follow-up. There were no significant association between DFS, OS and CD44 expression, respectively. (Log-rank p=0.13). (Log-rank p=0.10).
The results from this study suggest that CD44 is clinically associated with stage of breast cancers. From the survival analysis, there was no statistical difference in overall survival and disease free survival with respect to CD44 expression. Further studies larger sample sizes are recommended for further investigation.
乳腺癌（BC）是全球最常见的恶性肿瘤之一。CD44 的表达与乳腺癌中的细胞增殖、浸润、血管生成、转移和预后相关，但 CD44 功能的确切机制仍不清楚。本研究评估了原发性 HER2 阳性乳腺癌中 CD44 的表达。这些结果可用于确定乳腺癌患者的无病生存率和总生存率。
我们研究了 2011 年 3 月至 2019 年 6 月期间 100 例 HER2 阳性浸润性乳腺癌患者的标本。对所有标本均行 CD44 免疫组织化学染色。评估其 CD44 与临床病理参数和预后的关系。
高 CD44 表达在 68 例（68%）患者中，低表达在 32 例（32%）患者中。CD44 表达与分期显著相关（p=0.007）。除分期外，DFS、OS 与其他临床病理参数之间均无显著相关性（HR=3.67，95%CI=1.16-11.56，P=0.03）（HR=0.85，95%CI=2.22-32.90，P=0.002）。在随访结束时，有 20%的患者死亡。DFS 和 OS 与 CD44 表达之间均无显著相关性（Log-rank p=0.13）。（Log-rank p=0.10）。
本研究结果表明，CD44 与乳腺癌的分期具有临床相关性。从生存分析来看，CD44 表达与总生存率和无病生存率无统计学差异。建议进一步开展更大样本量的研究进行进一步探讨。
